Having a go at spinal muscular atrophy with spinraza

O. Balaji, D. Amita, Rt Sereen, Ap Navin

Research output: Contribution to journalReview article

Abstract

Spinal muscular atrophy (SMA), a neurological condition which is genetically mediated is the second most common infantile disease causing morbidity and mortality next to cystic fibrosis. It is of five different types with each type having different severity outcomes. For almost three decades, only supportive measures were advocated in the treatment of SMA. Recently, Biogen’s Spinraza came out as the first disease modifying therapy to treat infantile as well as adult SMA. This review throws light on the pharmacological aspects of the drug; its approval by Food and Drug Administration and various completed clinical trials as well ongoing clinical trials.

Original languageEnglish
Pages (from-to)16-18
Number of pages3
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume10
Issue number6
DOIs
Publication statusPublished - 01-01-2017
Externally publishedYes

Fingerprint

Spinal Muscular Atrophy
Clinical Trials
Spinal Muscular Atrophies of Childhood
United States Food and Drug Administration
Cystic Fibrosis
Pharmacology
Morbidity
Mortality
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Balaji, O. ; Amita, D. ; Sereen, Rt ; Navin, Ap. / Having a go at spinal muscular atrophy with spinraza. In: Asian Journal of Pharmaceutical and Clinical Research. 2017 ; Vol. 10, No. 6. pp. 16-18.
@article{869b763eaf8446a8bf233b6d649eaeac,
title = "Having a go at spinal muscular atrophy with spinraza",
abstract = "Spinal muscular atrophy (SMA), a neurological condition which is genetically mediated is the second most common infantile disease causing morbidity and mortality next to cystic fibrosis. It is of five different types with each type having different severity outcomes. For almost three decades, only supportive measures were advocated in the treatment of SMA. Recently, Biogen’s Spinraza came out as the first disease modifying therapy to treat infantile as well as adult SMA. This review throws light on the pharmacological aspects of the drug; its approval by Food and Drug Administration and various completed clinical trials as well ongoing clinical trials.",
author = "O. Balaji and D. Amita and Rt Sereen and Ap Navin",
year = "2017",
month = "1",
day = "1",
doi = "10.22159/ajpcr.2017.v10i6.17502",
language = "English",
volume = "10",
pages = "16--18",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "6",

}

Having a go at spinal muscular atrophy with spinraza. / Balaji, O.; Amita, D.; Sereen, Rt; Navin, Ap.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 6, 01.01.2017, p. 16-18.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Having a go at spinal muscular atrophy with spinraza

AU - Balaji, O.

AU - Amita, D.

AU - Sereen, Rt

AU - Navin, Ap

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Spinal muscular atrophy (SMA), a neurological condition which is genetically mediated is the second most common infantile disease causing morbidity and mortality next to cystic fibrosis. It is of five different types with each type having different severity outcomes. For almost three decades, only supportive measures were advocated in the treatment of SMA. Recently, Biogen’s Spinraza came out as the first disease modifying therapy to treat infantile as well as adult SMA. This review throws light on the pharmacological aspects of the drug; its approval by Food and Drug Administration and various completed clinical trials as well ongoing clinical trials.

AB - Spinal muscular atrophy (SMA), a neurological condition which is genetically mediated is the second most common infantile disease causing morbidity and mortality next to cystic fibrosis. It is of five different types with each type having different severity outcomes. For almost three decades, only supportive measures were advocated in the treatment of SMA. Recently, Biogen’s Spinraza came out as the first disease modifying therapy to treat infantile as well as adult SMA. This review throws light on the pharmacological aspects of the drug; its approval by Food and Drug Administration and various completed clinical trials as well ongoing clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85020870630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020870630&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i6.17502

DO - 10.22159/ajpcr.2017.v10i6.17502

M3 - Review article

VL - 10

SP - 16

EP - 18

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 6

ER -